成人先天性免疫缺陷病患者中异基因干细胞移植与保守治疗的比较
该回顾性病例对照研究比较了79例接受异基因造血干细胞移植的严重先天性免疫缺陷成人患者与202例匹配的非移植患者,中位随访4.8年,移植组5年无病生存率58%高于非移植组33%(P=.007),1年移植相关死亡率为13%。
要点
- 移植组5年估计无病生存率为58%,非移植组为33%(P=.007)。
- 1年移植相关死亡率为13%,中位移植年龄21岁。
- 非移植患者存在持续严重事件风险,平均累积复发事件数高于移植组。
核心结论
- 异基因造血干细胞移植可预防成人先天性免疫缺陷相关的进行性并发症,其获益可能超过移植相关死亡的负面影响。
研究设计与样本
- 回顾性比较移植与非移植匹配成人严重先天性免疫缺陷患者结局的病例对照研究。
- 79例患者(年龄≥15岁)于2008年至2018年间因先天性免疫缺陷接受异基因造血干细胞移植,其中慢性肉芽肿病20例、各种联合免疫缺陷59例。
- 非移植患者来自法国遗传性免疫缺陷参考中心登记处,盲法识别用于病例对照分析,每个索引患者匹配≤3例对照,无替换。
- 匹配因素包括出生年代、末次评估年龄大于索引患者移植时年龄、慢性肉芽肿病或联合免疫缺陷、自身免疫/淋巴增殖并发症。
- 共纳入281例患者(移植79例,非移植202例),移植中位年龄21岁,中位随访4.8年(四分位距2.5-7.2)。
主要发现
- 移植指征主要为淋巴增殖性疾病(23例)或结肠炎(15例)。
- 1年移植相关死亡率为13%。
- 移植组5年估计无病生存率为58%,非移植组为33%(P=.007)。
- 非移植患者存在持续严重事件风险,平均累积复发事件数高于移植组。
- 剔除普通变异型免疫缺陷患者及其匹配移植患者后的敏感性分析确认了上述结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (alloSCT) is curative for severe inborn errors of immunity (IEIs), with recent data suggesting alloSCT in adulthood is safe and effective in selected patients. However, questions remain regarding the indications for and optimal timing of transplant. We retrospectively compared outcomes of transplanted vs matched nontransplanted adults with severe IEIs. Seventy-nine patients (aged ≥ 15 years) underwent alloSCT between 2008 and 2018 for IEIs such as chronic granulomatous disease (n = 20) and various combined immune deficiencies (n = 59). A cohort of nontransplanted patients from the French Centre de Référence Déficits Immunitaires Héréditaires registry was identified blindly for case-control analysis, with ≤3 matched controls per index patient, without replacement. The nontransplanted patients were matched for birth decade, age at last review greater than index patient age at alloSCT, chronic granulomatous disease or combined immune deficiencies, and autoimmune/lymphoproliferative complications. A total of 281 patients were included (79 transplanted, 202 nontransplanted). Median age at transplant was 21 years. Transplant indications were mainly lymphoproliferative disease (n = 23) or colitis (n = 15). Median follow-up was 4.8 years (interquartile range, 2.5-7.2). One-year transplant-related mortality rate was 13%. Estimated disease-free survival at 5 years was higher in transplanted patients (58% vs 33%; P = .007). Nontransplanted patients had an ongoing risk of severe events, with an increased mean cumulative number of recurrent events compared with transplanted patients. Sensitivity analyses removing patients with common variable immune deficiency and their matched transplanted patients confirm these results. AlloSCT prevents progressive morbidity associated with IEIs in adults, which may outweigh the negative impact of transplant-related mortality.
引用
- Cheminant M, Fox TA, Alligon M, et al. Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity. Blood. 2023. PMID: 36167031. doi:10.1182/blood.2022015482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。